BioLife Solutions Gestion
Gestion contrôle des critères 3/4
Le PDG BioLife Solutions est Rod de Greef, nommé en Oct2023, a un mandat de 2.92 ans. La rémunération annuelle totale est $ 10.47M, composée du salaire de 7.3% et des bonus 92.7%, y compris les actions et options de la société. détient directement 0.79% des actions de la société, d'une valeur de $ 13.68M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.9 ans et 17.8 ans.
Informations clés
Rod de Greef
Directeur général
US$10.5m
Rémunération totale
| Pourcentage du salaire du PDG | 7.29% |
| Durée du mandat du directeur général | 2.9yrs |
| Propriété du PDG | 0.8% |
| Durée moyenne d'occupation des postes de direction | 2.9yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 17.8yrs |
Mises à jour récentes de la gestion
Recent updates
BioLife Solutions (BLFS) Stock Could Be 19.7% Undervalued After Portfolio Re Entry
BioLife Solutions (BLFS) is back in focus after Prosper Stars & Stripes added the stock to its portfolio again, pointing to the company’s renewed emphasis on core biopreservation media as well as cell and gene therapy exposure. See our latest analysis for BioLife Solutions. Recent trading reflects that shift in attention, with BioLife Solutions showing a 35.84% 90 day share price return and a 22.71% 1 year total shareholder return, while the current share price sits at $26.04 as investors...
BLFS: New Biopreservation Center Will Support Stronger Margins And Future Returns
Analysts have nudged their price target for BioLife Solutions higher to align with a fair value estimate of about US$32.44 per share, up from roughly US$31.30. This adjustment reflects updated assumptions around slightly lower revenue growth, a modestly higher discount rate, stronger profit margins, and a somewhat lower future P/E multiple.BioLife Solutions: Back To Basics Is Getting Traction (Rating Upgrade)
Summary After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses that it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing. While the shares are not cheap, revenue growth is likely at 20%+ as more client therapies become commercial. Read the full article on Seeking AlphaBioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Investors Still Waiting For A Pull Back In BioLife Solutions, Inc. (NASDAQ:BLFS)
When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...Expanding Cell And Gene Therapy Workflows Will Shape Future Opportunities
Market leadership in cell and gene therapy, combined with expanded high-value product offerings, drives strong revenue and margin growth opportunities.An Intrinsic Calculation For BioLife Solutions, Inc. (NASDAQ:BLFS) Suggests It's 44% Undervalued
Key Insights BioLife Solutions' estimated fair value is US$44.43 based on 2 Stage Free Cash Flow to Equity BioLife...With BioLife Solutions, Inc. (NASDAQ:BLFS) It Looks Like You'll Get What You Pay For
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales...Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 27% after a shaky period...Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?
BioLife Solutions, Inc. ( NASDAQ:BLFS ), might not be a large cap stock, but it saw a significant share price rise of...Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results
BioLife Solutions, Inc. ( NASDAQ:BLFS ) investors will be delighted, with the company turning in some strong numbers...Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Key Insights BioLife Solutions' estimated fair value is US$31.49 based on 2 Stage Free Cash Flow to Equity BioLife...Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
BioLife Solutions, Inc. ( NASDAQ:BLFS ), is not the largest company out there, but it led the NASDAQCM gainers with a...Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, BioLife Solutions fair value estimate is US$24.10 BioLife...Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 25% after a shaky period...Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders will have a reason to smile today, with the analysts making...Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
While BioLife Solutions, Inc. ( NASDAQ:BLFS ) might not have the largest market cap around , it received a lot of...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$49m |
| Mar 31 2026 | n/a | n/a | -US$11m |
| Dec 31 2025 | US$10m | US$763k | -US$12m |
| Sep 30 2025 | n/a | n/a | -US$14m |
| Jun 30 2025 | n/a | n/a | -US$15m |
| Mar 31 2025 | n/a | n/a | -US$5m |
| Dec 31 2024 | US$7m | US$744k | -US$9m |
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$13m |
| Dec 31 2023 | US$6m | US$199k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$79m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | US$2m | US$450k | US$388k |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$1m | US$412k | -US$9m |
| Sep 30 2021 | n/a | n/a | US$5m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$3m | US$391k | US$2m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$16m |
| Mar 31 2020 | n/a | n/a | US$39m |
| Dec 31 2019 | US$1m | US$403k | -US$2m |
Rémunération vs marché: La rémunération totale de Rod ($USD 10.47M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.19M ).
Rémunération et revenus: La rémunération de Rod a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Rod de Greef (66 yo)
Mr. Roderick de Greef, also known as Rod, serves as Director of BioLife Solutions, Inc. since January 03, 2023 and serves as its Chief Executive Officer & Chairman since October 20, 2023. He had been Presi...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman | 2.9yrs | US$10.47m | 0.79% $ 13.7m | |
| Chief Financial Officer | 4.8yrs | US$3.27m | 0.44% $ 7.5m | |
| Chief Technology Officer | 1.8yrs | US$2.15m | 0.097% $ 1.7m | |
| Chairman of Scientific Advisory Board | 6.8yrs | US$3.19m | 0.79% $ 13.7m | |
| Chief Commercial Officer | 1.8yrs | US$1.93m | 0.33% $ 5.8m |
Gestion expérimentée: L'équipe de direction de BLFS est considérée comme expérimentée (ancienneté moyenne 2.9 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman | 3.7yrs | US$10.47m | 0.79% $ 13.7m | |
| Chairman of Scientific Advisory Board | no data | US$3.19m | 0.79% $ 13.7m | |
| Member of Scientific Advisory Board | 19.9yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 19yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 19.9yrs | pas de données | pas de données | |
| Member of the Scientific Advisory Board | no data | US$284.00k | pas de données | |
| Member of Scientific Advisory Board | 19yrs | pas de données | pas de données | |
| Member of the Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Lead Director | 5.4yrs | US$299.17k | 0.055% $ 950.1k | |
| Independent Director | 4.9yrs | US$254.17k | 0.11% $ 1.9m | |
| Member of Scientific Advisory Board | 17.8yrs | pas de données | pas de données | |
| Independent Director | 1.5yrs | US$234.41k | 0.028% $ 490.7k |
Conseil d'administration expérimenté: Le conseil d'administration de la BLFS est chevronné et expérimenté ( 17.8 années d'ancienneté moyenne).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/09 19:40 |
| Cours de l'action en fin de journée | 2026/09/09 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
BioLife Solutions, Inc. est couverte par 17 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| George Zavoico | B. Riley Securities, Inc. |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |